康希诺事件点评:PCV13I获批上市 三重优势提供更优保护

湘财证券股份有...
24 Jun

事件:6 月21 日,公司发布关于13 价肺炎球菌多糖结合疫苗(CRM197/破伤风类毒素)于2025 年6 月20 日获得药品注册证书的公告。核心要点:公司PCV13i 优佩欣具有三重优势,可提供更优保护肺炎球菌性疾病是全球严重的公共卫生问题之一。公司自主研发的13 价肺炎球菌多糖结合疫苗(PCV13i)优佩欣为公司首款肺炎疫苗产品,也是我国首款使用CRM197(白喉毒素无毒突变体)和TT(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10